Loading
A phase 2/3 trial of Umbralisib and Venetoclax in Chronic lymphocytic leukaemia, run by TG Therapeutics, Inc., recorded as terminated on the registry.
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) is a phase 2/3 interventional study registered as NCT03801525 by TG Therapeutics, Inc., with 277 participants recorded, started 2019-05-16 and due to reach its primary completion in 2022-12-20. Interventions recorded: Ublituximab, Umbralisib, Venetoclax. Conditions recorded: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.
Linked to the drug Umbralisib because the registry names it among its interventions and Chronic lymphocytic leukaemia among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
277 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2024-04-19), not from a publication
SourceFigures from the ClinicalTrials.gov results section (first posted 2024-04-19), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Phase 2: Complete Response (CR) Rate as Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 Criteriaprimary | Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) | 149 | 33.6% | - | - | link |
| Phase 2: Overall Response Rate (ORR) Per iwCLL 2018 Criteriaprimary | Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V) | 149 | 93.3% | - | - | link |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Umbralisib, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Umbralisib and the tag pipeline.
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/